Cargando…

Early experience with remdesivir in SARS-CoV-2 pneumonia

At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients h...

Descripción completa

Detalles Bibliográficos
Autores principales: Durante-Mangoni, Emanuele, Andini, Roberto, Bertolino, Lorenzo, Mele, Ferruccio, Florio, Letizia Lucia, Murino, Patrizia, Corcione, Antonio, Zampino, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229436/
https://www.ncbi.nlm.nih.gov/pubmed/32418190
http://dx.doi.org/10.1007/s15010-020-01448-x
_version_ 1783534762176020480
author Durante-Mangoni, Emanuele
Andini, Roberto
Bertolino, Lorenzo
Mele, Ferruccio
Florio, Letizia Lucia
Murino, Patrizia
Corcione, Antonio
Zampino, Rosa
author_facet Durante-Mangoni, Emanuele
Andini, Roberto
Bertolino, Lorenzo
Mele, Ferruccio
Florio, Letizia Lucia
Murino, Patrizia
Corcione, Antonio
Zampino, Rosa
author_sort Durante-Mangoni, Emanuele
collection PubMed
description At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19.
format Online
Article
Text
id pubmed-7229436
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72294362020-05-18 Early experience with remdesivir in SARS-CoV-2 pneumonia Durante-Mangoni, Emanuele Andini, Roberto Bertolino, Lorenzo Mele, Ferruccio Florio, Letizia Lucia Murino, Patrizia Corcione, Antonio Zampino, Rosa Infection Case Report At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19. Springer Berlin Heidelberg 2020-05-16 2020 /pmc/articles/PMC7229436/ /pubmed/32418190 http://dx.doi.org/10.1007/s15010-020-01448-x Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Durante-Mangoni, Emanuele
Andini, Roberto
Bertolino, Lorenzo
Mele, Ferruccio
Florio, Letizia Lucia
Murino, Patrizia
Corcione, Antonio
Zampino, Rosa
Early experience with remdesivir in SARS-CoV-2 pneumonia
title Early experience with remdesivir in SARS-CoV-2 pneumonia
title_full Early experience with remdesivir in SARS-CoV-2 pneumonia
title_fullStr Early experience with remdesivir in SARS-CoV-2 pneumonia
title_full_unstemmed Early experience with remdesivir in SARS-CoV-2 pneumonia
title_short Early experience with remdesivir in SARS-CoV-2 pneumonia
title_sort early experience with remdesivir in sars-cov-2 pneumonia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229436/
https://www.ncbi.nlm.nih.gov/pubmed/32418190
http://dx.doi.org/10.1007/s15010-020-01448-x
work_keys_str_mv AT durantemangoniemanuele earlyexperiencewithremdesivirinsarscov2pneumonia
AT andiniroberto earlyexperiencewithremdesivirinsarscov2pneumonia
AT bertolinolorenzo earlyexperiencewithremdesivirinsarscov2pneumonia
AT meleferruccio earlyexperiencewithremdesivirinsarscov2pneumonia
AT florioletizialucia earlyexperiencewithremdesivirinsarscov2pneumonia
AT murinopatrizia earlyexperiencewithremdesivirinsarscov2pneumonia
AT corcioneantonio earlyexperiencewithremdesivirinsarscov2pneumonia
AT zampinorosa earlyexperiencewithremdesivirinsarscov2pneumonia